Free Post Earnings Research Report: Diamondback Energy’s Q3 Results Improved and Outshined Estimates

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors free earnings report on Diamondback Energy, Inc. (NASDAQ: FANG) has freshly been issued to its members, and you can also sign up to view this report at www.active-investors.com/registration-sg/?symbol=FANG. The Company posted its financial results on November 06, 2017, for the third quarter fiscal 2017 (Q3 FY17). The Midland, Texas-based Company’s total revenues and adjusted net income per diluted share grew on a y-o-y basis, topping Wall Street’s estimates. Register today and get free access to our complimentary member’s area where many more reports are available:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Diamondback Energy most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=FANG

Earnings Highlights and Summary

During Q3 FY17, Diamondback Energy total operating revenues came in at $301.25 million, which was higher than $142.13 million recorded at the end of Q3 FY16. Total revenues for the reported quarter outperformed market expectations of $299.9 million.

The energy exploration and production Company reported net income attributable to Diamondback Energy of $73.02 million, or $0.74 per diluted share, in Q3 FY17 versus net loss attributable to Diamondback Energy of $2.23 million, or $0.03 loss per diluted share, in Q3 FY16. The Company’s adjusted net income attributable to Diamondback Energy surged during Q3 FY17 to $131.07 million, or $1.33 per diluted share, from $122.56 million, or $1.25 per share, in the prior year’s comparable quarter. Meanwhile, market analysts had forecasted adjusted net income of $1.25 per share for Q3 FY17.

Operating Metrics

Diamondback Energy total expenses during Q3 FY17 increased to $158.61 million from $135.44 million in the past year’s comparable quarter. The Company’s cash operating costs reduced to $7.67 per BOE during Q3 FY17 from $9.15 per BOE in Q3 FY16.

The Company reported income from operations of $142.64 million in Q3 FY17 versus $6.69 million in Q3 FY16. Furthermore, adjusted EBITDA attributable to Diamondback Energy came in at $232.46 million for Q3 FY17 compared to $218.43 million in the year-ago same period.

In Q3 FY17, Diamondback Energy’ oil production volume increased to 5.68 thousand barrels per day (MBbls) from 3.00 MBbls in Q3 FY16. Natural gas production volume totaled 5.94 million cubic feet (MMcf) for Q3 FY17 versus 2.67 MMcf in the prior year’s comparable quarter. Natural gas liquids (NGL) production volume increased during Q3 FY17 to 1,155 thousand barrels (MBbls) from 687 MBbls in Q3 FY16. Oil Equivalents production volume was 7,823 million barrels of oil equivalent (MBOE) in Q3 FY17, up from 4,133 MBOE in the prior year’s same quarter. Average daily production was 85,029 barrels of oil equivalent per day (BOE/d) during Q3 FY17, up from 44,923 (BOE/d) in Q3 FY16.

During Q3 FY17, Diamondback Energy averaged nine rigs, drilled 42 gross horizontal wells and turned 24 operated horizontal wells to production.

Cash Matters and Balance Sheet

For the nine months ended on September 30, 2017, Diamondback Energy’s net cash provided by operating activities was $638.02 million compared to $226.35 million in the prior year’s corresponding period. The Company’s cash and cash equivalents balance stood at $30.21 million, as on September 30, 2017, compared to $1.67 billion, at the close of books on December 31, 2016. Additionally, the Company’s total long-term debt increased to $1.26 billion as on September 30, 2017, from $1.11 billion as on December 31, 2016.

Guidance

In its guidance for FY17, Diamondback Energy raised total net production to the range of 77.5 MBoe/d to 78.5 MBoe/d from the prior year’s guidance range of 74.0 MBoe/d to 78.0 MBoe/d. Furthermore, the Company narrowed capital expenditure guidance range for FY17 to $850 million to $900 million from prior year range of $800 million to $950 million.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, Diamondback Energy’s stock slightly declined 0.50%, ending the trading session at $111.03.

Volume traded for the day: 827.17 thousand shares.

Stock performance in the last month – up 2.55%; previous three-month period – up 18.15%; past twelve-month period – up 9.38%; and year-to-date – up 9.87%

After yesterday’s close, Diamondback Energy’s market cap was at $10.90 billion.

Price to Earnings (P/E) ratio was at 26.88.

The stock is part of the Basic Materials sector, categorized under the Independent Oil & Gas industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Free Post Earnings Research Report: DDR’s Operating FFO Beats Expectations

Stock Monitor: At Home Group Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors free earnings report on DDR Corp. (NYSE: DDR) has freshly been issued to its members, and you can also sign up to view this report at www.active-investors.com/registration-sg/?symbol=DDR. The Company posted its financial results on November 02, 2017, for the third quarter fiscal 2017. Register today and get free access to our complimentary member’s area where many more reports are available:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for At Home Group Inc. (NYSE: HOME), which also belongs to the Financial sector as the Company DDR Corp. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=HOME

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, DDR Corp. most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=DDR

Earnings Highlights and Summary

For three months ended September 30, 2017, DDR’s total revenues decreased 10.2% to $220.13 million from $245.24 million in Q3 FY16. The Company’s total revenue was below analysts’ expectations of $222.2 million.

For the reported quarter, DDR’s net loss was $7.40 million, compared to net loss of $65.95 million in Q3 FY16. The lower net loss was due to the reduction of $15.4 million in the valuation allowance recorded in the first quarter of 2017 on the Company’s preferred investment in two joint ventures, lower impairment charges and a higher gain on sale of real estate assets. During Q3 FY17, the Company’s diluted EPS was negative $0.02 compared to negative $0.18 in the same period last year.

For the reported quarter, DDR’s funds from operation (FFO) decreased 61.4% to $46.34 million from $120.14 million in Q3 FY16. During Q3 FY17, the Company’s FFO per share decreased 60.6% to $0.13 from $0.33 in the same period last year.

For the reported quarter, DDR’s operating FFO decreased 7.8% to $111.24 million from $120.64 million in Q3 FY16. During Q3 FY17, the Company’s operating FFO per share decreased 9.1% to $0.30 from $0.33 in the same period last year. The decrease was due to dilution from deleveraging and a decline in NOI from Puerto Rico. Operating FFO per share surpassed analysts’ expectations of $0.27.

Operating Results

During Q3 FY17, DDR’s net operating income (NOI) decreased 9.3% to $160.57 million from $177.07 million in the same period last year. For the reported quarter, the Company’s same-store net operating income (SSNOI) including Puerto Rico decreased 0.7% to $229.21 million from $230.95 million in Q3 FY16. For the reported quarter, the Company’s SSNOI excluding Puerto Rico decreased 0.2% to $208.99 million from $209.32 million in Q3 FY16.

For the reported quarter, the Company’s portfolio leased rate on a pro rata basis was 93.4% compared to 95.4% in Q3 FY16. During Q3 FY17, the Company’s base rent per occupied square foot increased 5.2% on a pro-rata basis to $16.16 from $15.36 in the third quarter of 2016. During Q3 FY17, DDR sold 16 shopping centers and land parcels for a total of $392.1 million.

During Q3 FY17, the Company generated new leasing spreads of 6.8% and renewal leasing spreads of 6.1% on a pro-rata basis including Puerto Rico.

Balance Sheet

As on September 30, 2017, DDR’s cash decreased 40% to $18.27 million from $30.43 million on December 31, 2016. For the reported quarter, the Company’s unsecured debt decreased 3.6% to $2.81 billion from $2.91 billion in Q4 FY16.

During Q3 FY17, DDR extended the maturity of its revolving credit facilities and enhanced borrowing capacity to $1.0 billion and extended the maturity of $200 million of $400 million unsecured term loan.

On November 10, 2017, the Company’s Board of directors declared a dividend of $0.19 per share payable on January 05, 2018, to shareholders of record at the close of business on December 12, 2017.

Outlook

For FY17, the Company expects same-store NOI growth to be in the range of negative 0.5% to positive 5% for the Continental US Portfolio.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, DDR Corp.’s stock declined 1.36%, ending the trading session at $7.96.

Volume traded for the day: 6.21 million shares, which was above the 3-month average volume of 4.41 million shares.

After yesterday’s close, DDR Corp.’s market cap was at $2.90 billion.

The stock has a dividend yield of 9.55%.

The stock is part of the Financial sector, categorized under the REIT – Retail industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Free Post Earnings Research Report: DENTSPLY SIRONA’s Revenue Grew 5.8%; Adjusted EPS Surged 6.1%

Stock Monitor: Cooper Cos. Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors free earnings report on DENTSPLY SIRONA Inc. (NASDAQ: XRAY) has freshly been issued to its members, and you can also sign up to view this report at www.active-investors.com/registration-sg/?symbol=XRAY. The Company posted its financial results on November 02, 2017, for the third quarter fiscal 2017. The Company’s revenue and adjusted EPS surpassed analysts’ expectations. Register today and get free access to our complimentary member’s area where many more reports are available:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for The Cooper Companies, Inc. (NYSE: COO), which also belongs to the Healthcare sector as the Company DENTSPLY SIRONA. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=COO

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, DENTSPLY SIRONA most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=XRAY

Earnings Highlights and Summary

For three months ended September 30, 2017, DENTSPLY’s net revenues increased 5.8% to $1.01 billion from $954.2 million in Q3 FY16. For the reported quarter, the Company’s net revenue excluding precious metals increased 6.5% to $999.8 million from $939.2 million in Q3 FY16. The Company’s net revenue surpassed analysts’ expectations of $978.0 million.

For the reported quarter, the Company’s net revenue in the US increased 8.4% to $363.8 million on a y-o-y basis and net revenue excluding precious metals increased 8.4% to $362.3 million on a y-o-y basis. For the reported quarter, the Company’s net revenue in Europe increased 8.2% to $386.6 million on a y-o-y basis and net revenue excluding precious metals increased 9% to $379.6 million on a y-o-y basis. For the reported quarter, the Company’s net revenue in rest of the world decreased 1% to $258.8 million on a y-o-y basis and net revenue excluding precious metals increased 0.5% to $257.9 million on a y-o-y basis.

During Q3 FY17, DENTSPLY’s gross profit increased 8.8% to $559 million from $513.6 million in the same period last year. For the reported quarter, the Company’s gross margin increased 160 basis points to 55.4% of revenue from 53.8% of revenue in the third quarter of last year.

During Q3 FY17, DENTSPLY’s operating income decreased 14.8% to $107.9 million from $126.6 million in the same period last year. For the reported quarter, the Company’s operating margin decreased 260 basis points to 10.7% of revenue from 13.3% of revenue in the third quarter of last year. For the reported quarter, the Company’s adjusted operating margin increased 30 basis points to 21.1% of revenue from 20.8% of revenue in the third quarter of last year.

During Q3 FY17, DENTSPLY’s earnings before tax (EBT) decreased 16.7% to $97.6 million from $117.1 million in the same period last year. For the reported quarter, the Company’s EBT margin decreased 260 basis points to 9.7% of revenue from 12.3% of revenue in the third quarter of last year.

For the reported quarter, DENTSPLY’s net income decreased 2.1% to $90.6 million from $92.5 million in Q3 FY16. During Q3 FY17, the Company’s diluted EPS was $0.39, on par with $0.39 in the same period last year. For the reported quarter, DENTSPLY’s adjusted net income increased 5.6% to $164.3 million on a y-o-y basis from $155.6 million in Q3 FY16. During Q3 FY17, the Company’s adjusted diluted EPS increased 6.1% to $0.70 on a y-o-y basis from $0.66 in the same period last year. Adjusted diluted EPS surpassed analysts’ expectations of $0.66.

DENTSPLY’s Segment Details

Implants, CAD/CAM, Prosthetics & Healthcare During Q3 FY17, the Company’s Implants, CAD/CAM, Prosthetics & Healthcare segment’s net revenue increased 3.1% to $394.8 million from $382.8 million in the same period last year. For the reported quarter, the segment’s adjusted operating income increased 1.2% to $85.2 million from $84.2 million in Q3 FY16.

Chairside Consumables & Endodontics – During Q3 FY17, the Company’s Chairside Consumables & Endodontics segment’s net revenue increased 7.6% to $412.6 million from $383.5 million in the same period last year. For the reported quarter, the segment’s adjusted operating income increased 14.5% to $126.9 million from $110.8 million in Q3 FY16.

Imaging, Treatment Centers & Orthodontics –During Q3 FY17, the Company’s Imaging, Treatment Centers & Orthodontics segment’s net revenue increased 7.4% to $201.8 million from $187.9 million in the same period last year. For the reported quarter, the segment’s adjusted operating income increased 73.9% to $40.0 million from $23.0 million in Q3 FY16.

Balance Sheet

As on September 30, 2017, DENTSPLY’s cash and cash equivalents decreased 3.6% to $370 million from $383.9 million on December 31, 2016. For the reported quarter, the Company’s long-term debt increased 5.9% to $1.60 billion from $1.51 billion in Q4 FY16

In the first nine months of 2017, the Company’s cash provided by operating activities increased 9.4% to $373 million from $341 million in the same period last year.

On December 12, 2017, the Company’s Board of Directors declared a quarterly cash dividend of $0.088 per share payable on January 12, 2018, to holders of record on December 29, 2017.

Outlook

For FY17, the Company expects adjusted diluted EPS to be in the range of $2.65 to $2.70.

Stock Performance Snapshot

December 14, 2017 – At Thursday’s closing bell, DENTSPLY SIRONA’s stock was slightly down 0.62%, ending the trading session at $65.65.

Volume traded for the day: 937.20 thousand shares.

Stock performance in the last month – up 0.40%; previous three-month period – up 10.63%; past twelve-month period – up 10.02%; and year-to-date – up 13.72%

After yesterday’s close, DENTSPLY SIRONA’s market cap was at $15.20 billion.

The stock has a dividend yield of 0.53%.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ShareTradingEducation.com releases new 'Super 10 ETF Portfolio' Signals Service Launch for When to Buy, Hold & Sell Australian ETFs

New Signals Service Launch for When to Buy, Hold & Sell Australian ETFs

“Our new ‘Super 10 ETF Portfolio’ Signals Service will make it much easier for Australian ETF Investors to tackle the 3 main problems of WHICH ETFs to buy, WHEN to buy and, more importantly, when to SELL.”

ShareTradingEducation.com has developed an innovative ‘Super 10 ETF Portfolio’ Signals Service to help Australian ETF investors know with confidence:

  • WHICH Exchange Traded Funds (ETFs) to Buy,
  • When to BUY those ETFs
  • When to HOLD them and
  • When to SELL

The new ‘Super 10 ETF Portfolio’ Signals Service provides step-by-step assistance to lead members through the complete ETF Investing process, from Entry to Exit. This includes a strong emphasis on Money and Risk Management to protect capital and profits.

Since 2005, ShareTradingEducation.com is the home of Jim Berg’s hands-on weekly mentoring-style ‘Investing and Online Trading’ stock market Report. Jim has been trading and investing in the markets for over 30 years, including 18 years as a professional broker.

Jim Berg advised his Report members to switch to cash in early Jan 2008, then gave a re-entry Signal in June 2009 Those members who followed his lead did not lose millions of dollars between them during the GFC.

Angela Atkinson, CEO of ShareTradingEducation.com, said: “Over a quarter of a million Australians now have ETFs in their portfolio. The increased liquidity and accessibility of ETFs is attracting investors of all ages – from Millennials, through Generation X to Baby Boomers.”

“There is currently an overwhelming total of over 250 ETFs to choose from in Australia alone! However, many may be in falling trends, so they may continue to fall in price. Others may be relatively illiquid.“

“The other challenge many new and experienced investors often face is that they do not know when to enter or exit a position.”

“Our new ‘Super 10 ETF Portfolio’ Signals Service will make it much easier for Australian ETF Investors to tackle the 3 main problems of WHICH ETFs to buy, WHEN to buy and, more importantly, when to SELL.”

“We select 10 liquid ETFs from the Australian and global markets which are in rising trends. Each ETF may be purchased in a similar way to shares on local share trading platforms in Australia, so there is no need to open a separate overseas account.”

“For each ETF, we suggest a maximum Buy Price and, most significantly, no less than 5 structured Exit Strategies should any individual ETF – or the whole notional portfolio – fall below pre-set levels.”

“On behalf of our ETF Signals members we monitor all 10 ETFs daily and provide weekly updates of prices, Stop Losses and summary status.”

“To help protect capital and profits, we will also notify Members when any Exit Signals are generated.” said Angela Atkinson.

Please note that whilst ETFs generally have lower volatility, they are still a financial product open to risks associated with market forces and unpredictable events which may affect their performance.”

The new ‘Super 10 ETF Portfolio’ Signals Service is designed to help Australians invest in ETFs with confidence. It is now available at ShareTradingEducation.com.

Share article on social media or email:

Loss of Revenue in African Telecom Industry is Likely to Drive the Growth of Africa Revenue Assurance Market 2017-2024

Revenue Assurance Market

Riding on the back of technology, businesses are expanding beyond boundaries. With rapid digitization, a spiked revenue is being tallied by service sectors

BROOKLYN, NEW YORK, UNITED STATES, December 14, 2017 /EINPresswire.com/ — “Revenue Assurance Market: Africa Demand Analysis & Opportunity Outlook 2023”

The Africa revenue assurance market is segmented into end user type such as small enterprise, medium enterprise and large enterprise. Among these segments, large enterprise segment is expected to experience remarkable growth over the forecast period. The expansion of large enterprise segment can be attributed to expanding product portfolios of the companies, which in turn, increasing risk of revenue leakage in the large companies. Moreover, increasing business complexities is also a major factor which is anticipated to escalate the demand for revenue assurance solutions and services during the forecast period.

Africa revenue assurance market is expected to register a robust CAGR over the forecast period. Moreover, Africa revenue assurance market is expected to reach at notable revenue by the end of 2024. The market is expected to expand on the back of a number of factors which are higher operational complexity, rising probability of revenue leakage, acquisition, merging and partnership in various business enterprises.

The telecom segment by industry type is likely to grow at remarkable pace during the forecast period. The loss of revenue in telecom sector of Africa is directly affecting the business of many telecom players in the region by decreasing the profitability. Further, telecom companies are looking forward to implement revenue assurance services and solutions in order to provide better services and generate feasible revenue.

Request Report Sample@ https://www.researchnester.com/sample-request/2/rep-id-158

Rising need for prevention and control of revenue leakage

The demand for revenue assurance service and solutions is expected to rise during the forecast period due to increasing need for fraud detection and to prevent internal revenue leakage in the business enterprises. Moreover, large and medium scale organizations are witnessing high revenue leakage due to factors such as acquisition, merging, collaboration, joint venture with other companies and increasing operational complexity. Growing operational complexity in large and medium scale organizations is likely to fuel the demand for revenue assurance service & solutions during the forecast period.

Currency fluctuation in African economies

Increasing volatility in African currency is also a major factor which is envisioned to lead companies to adopt revenue assurance solutions and services in order to prevent internal financial losses. Moreover, rising demand for better services and facilities from the consumers end is projected to open new avenues for the revenue assurance service providers in the region. Although, higher cost of assuring revenues is one of the major factors that are likely to inhibit the growth of the Africa Revenue Assurance Market in the near future.

The report titled “Revenue Assurance Market : Africa Demand Analysis & Opportunity Outlook 2023” delivers detailed overview of the Africa revenue assurance market in terms of market segmentation by service type, by deployment type, by industry type, by end user and by region. Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Here: https://www.researchnester.com/toc-request/1/rep-id-158

This report also provides the existing competitive scenario of some of the key players of the Africa revenue assurance market which includes company profiling of Accenture PLC, Ericsson AB, Hewlett Packard, IBM Corp., Nokia Solutions and Networks, Wedo Technologies, Subex Limited, Cvidya (Amdocs). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the Africa revenue assurance market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Buy This Premium Reports Now @ https://www.researchnester.com/payment/rep-id-158

Ajay Daniel
Research Nester
+1 646 586 9123
email us here

Technological Advancement in Healthcare Devices is Projected to Flourish the Growth of Organ on a Chip Market in future

Organ on a Chip

The global organ on a chip market is expected to grow at a robust growth over the forecast period i.e. 2017-2024. Further, growing prevalence of chronic

BROOKLYN, NEW YORK, UNITED STATES, December 14, 2017 /EINPresswire.com/ — “Organ on a Chip Market: Global Demand Analysis & Opportunity Outlook 2024”

The global organ on a chip market is segmented into organ such as heart-on-chip, human-on-chip, intestine-on-chip, kidney-on-chip, liver-on-chip and lung-on-chip. Among these segments, lung-on-chip segment captured the largest market in overall organ on a chip market in 2016 and it is expected to continue its dominance during the forecast period. Likely, increasing incidences of lung failure across the globe is envisioned to propel the growth of lung-on-chip segment. Moreover, increasing government initiatives and funding is also positively impacting the growth of organ on a chip market.

Global organ on a chip market is expected to register a notable CAGR over the forecast period. Moreover, the global organ on a chip market is anticipated to reach at noteworthy revenue by 2024. The market is expected to expand on the back of increasing rate of organ transplant coupled with advancement in transplant technology.

In terms of regional platform, North America region captured the largest market of organ on a chip in terms of revenue owing to increasing utilization of organ on a chip in organ transplantation coupled with rising number of organ transplantation. Furthermore, U.S. is the prominent market in the region. Apart from this, Asia-Pacific region is the most lucrative market due to emerging economies such as India and China. In addition to this, increasing adoption of technologically advanced medical devices is expected to positively drive the growth of the market in the Asia Pacific region.

Request Report Sample@ https://www.researchnester.com/sample-request/2/rep-id-479

Rapid Development in Healthcare Infrastructure

Rapid development of healthcare industry in many nations across the globe is anticipated to positively impact the growth of the organ on a chip market. In addition to this, increasing spending on the development of healthcare infrastructure is envisioned to bolster the growth of organ on a chip market. For e.g. U.S. spends 16% of its GDP on healthcare. Similarly, substantial funding for the development of organ on chip is expected to fuel the growth of the organ on a chip market.

Favorable Government Initiatives

Government of various nations are emphasizing on adoption of better healthcare technologies. For instance, government of India has targeted development of 50 new technologies in 2016. Apart from this, technological advancement in organ transplant and favorable government initiatives such as research funding coupled with increasing research activities are anticipated to supplement the growth of organ on a chip market. Although, high cost associated with organ on a chip is expected to limit the growth of organ on a chip market. Moreover, lack of awareness in developing and undeveloped nations is hindering the growth of Organ on a Chip Market.

The report titled “Organ on a Chip Market: Global Demand Analysis & Opportunity Outlook 2024” delivers detailed overview of the global organ on a chip market in terms of market segmentation by organ and by region. Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Here:

https://www.researchnester.com/toc-request/1/rep-id-479

This report also provides the existing competitive scenario of some of the key players of the global organ on a chip market which includes company profiling of Emulate, Inc., AxoSim Techologies LLC, CN Bio Innovations Ltd., HµREL Corporation, Hepregen Corporation, InSphero AG, MIMETAS B.V, Nortis Inc., TARA Biosystems, Inc. and TissUse GmbH. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global organ on a chip market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Buy This Premium Reports Now @ https://www.researchnester.com/payment/rep-id-479

Ajay Daniel
Research Nester
+1 646 586 9123
email us here

Technological Advancement in Healthcare Devices is Projected to Flourish the Growth of Organ on a Chip Market in future

Organ on a Chip

The global organ on a chip market is expected to grow at a robust growth over the forecast period i.e. 2017-2024. Further, growing prevalence of chronic

BROOKLYN, NEW YORK, UNITED STATES, December 14, 2017 /EINPresswire.com/ — “Organ on a Chip Market: Global Demand Analysis & Opportunity Outlook 2024”

The global organ on a chip market is segmented into organ such as heart-on-chip, human-on-chip, intestine-on-chip, kidney-on-chip, liver-on-chip and lung-on-chip. Among these segments, lung-on-chip segment captured the largest market in overall organ on a chip market in 2016 and it is expected to continue its dominance during the forecast period. Likely, increasing incidences of lung failure across the globe is envisioned to propel the growth of lung-on-chip segment. Moreover, increasing government initiatives and funding is also positively impacting the growth of organ on a chip market.

Global organ on a chip market is expected to register a notable CAGR over the forecast period. Moreover, the global organ on a chip market is anticipated to reach at noteworthy revenue by 2024. The market is expected to expand on the back of increasing rate of organ transplant coupled with advancement in transplant technology.

In terms of regional platform, North America region captured the largest market of organ on a chip in terms of revenue owing to increasing utilization of organ on a chip in organ transplantation coupled with rising number of organ transplantation. Furthermore, U.S. is the prominent market in the region. Apart from this, Asia-Pacific region is the most lucrative market due to emerging economies such as India and China. In addition to this, increasing adoption of technologically advanced medical devices is expected to positively drive the growth of the market in the Asia Pacific region.

Request Report Sample@ https://www.researchnester.com/sample-request/2/rep-id-479

Rapid Development in Healthcare Infrastructure

Rapid development of healthcare industry in many nations across the globe is anticipated to positively impact the growth of the organ on a chip market. In addition to this, increasing spending on the development of healthcare infrastructure is envisioned to bolster the growth of organ on a chip market. For e.g. U.S. spends 16% of its GDP on healthcare. Similarly, substantial funding for the development of organ on chip is expected to fuel the growth of the organ on a chip market.

Favorable Government Initiatives

Government of various nations are emphasizing on adoption of better healthcare technologies. For instance, government of India has targeted development of 50 new technologies in 2016. Apart from this, technological advancement in organ transplant and favorable government initiatives such as research funding coupled with increasing research activities are anticipated to supplement the growth of organ on a chip market. Although, high cost associated with organ on a chip is expected to limit the growth of organ on a chip market. Moreover, lack of awareness in developing and undeveloped nations is hindering the growth of Organ on a Chip Market.

The report titled “Organ on a Chip Market: Global Demand Analysis & Opportunity Outlook 2024” delivers detailed overview of the global organ on a chip market in terms of market segmentation by organ and by region. Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Here:

https://www.researchnester.com/toc-request/1/rep-id-479

This report also provides the existing competitive scenario of some of the key players of the global organ on a chip market which includes company profiling of Emulate, Inc., AxoSim Techologies LLC, CN Bio Innovations Ltd., HµREL Corporation, Hepregen Corporation, InSphero AG, MIMETAS B.V, Nortis Inc., TARA Biosystems, Inc. and TissUse GmbH. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global organ on a chip market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Buy This Premium Reports Now @ https://www.researchnester.com/payment/rep-id-479

Ajay Daniel
Research Nester
+1 646 586 9123
email us here

Robust Number of Opthalmic Cases to Foster the Growth of Contact Lens Market in Future, according to Research Nester

Contact Lens

Global contact lens market was valued at USD 9.4 billion in 2015; further the market is estimated to reach USD 18.1 billion by the end of 2023

BROOKLYN, NEW YORK , UNITED STATES, December 14, 2017 /EINPresswire.com/ — “Contact Lens Market: Global Demand, Growth Analysis & Opportunity Outlook 2023”

The global contact lens market is segmented into design such as spherical contact lenses, toric contact lenses and multifocal contact lenses. Among these segments, multifocal contact lenses segment is expected to occupy top position in overall contact lens market during the forecast period. The growth of multifocal contact lens segment can be attributed to its multiple prescriptions capabilities. Furthermore, growing cases of age related ophthalmic disorders such as presbyopia are expected to augment the growth of multifocal contact lens market.

Global contact lens market is expected to flourish at a CAGR of 8.1% over the forecast period. Moreover, the global contact lens market is anticipated to garner USD18.1 Billion by the end of 2023. Increasing number of ophthalmic cases in youngsters and middle age population, rising awareness and increasing disposable income are some of the major factors behind the growth of contact lens market.

North America dominated the overall market of contact lens, with a market share of 32% and is expected to continue its dominance over the forecast period. Further, high demand for daily disposable lenses is anticipated to garner the growth of the contact lens market in North America region. Europe contact lenses market is projected to grow at significant pace in the next few years. Strong presence of key players and rapid growth in visual impairment rate in Germany is expected to foster the growth of the Europe contact lens market. Asia Pacific is anticipated to witness lucrative growth over the forecast period. Factors such as rising disposable income, enhanced brand preference and rising consumer towards contact lens are likely to impel the growth of contact lens market.

Request Report Sample@ https://www.researchnester.com/sample-request/2/rep-id-223

Increasing Number of Refractory Error and Weekend Eye Sight Cases

Increasing number of people suffering from refractive errors across the globe is anticipated to impel the demand for contact lens in the upcoming years. Moreover, rising adoption of contact lenses as a fashion accessory by youngsters is anticipated to foster the growth of contact lens market.

Advancements and Development of Innovative Contact lens

Innovations and advancements in the contact lenses such as improved oxygen flow supply are envisioned to bolster the growth of contact lens market over the forecast period. Apart from this, rising demand for custom contact lenses by youngsters is also anticipated to foster the growth of contact lens market. Although, problems and diseases associated with the use of contact lens is likely to inhibit the growth of the Global Contact Lens Market in the near future.

The report titled “Contact lens Market : Global Demand Analysis & Opportunity Outlook 2021” delivers detailed overview of the global contact lens market in terms of market segmentation by product type, by design, by technology and by region. Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Here: https://www.researchnester.com/toc-request/1/rep-id-223

This report also provides the existing competitive scenario of some of the key players of the global contact lens market which includes company profiling of Novartis International AG, Menicon Co. Ltd., STAAR Surgical, Carl Zeiss AG, SynergEyes Inc., Abbott Medical Optics, Inc., Essilor International S.A., Valeant Pharmaceuticals International Inc., Johnson & Johnson Services Inc., and Bausch and Lomb. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global contact lens market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Buy This Premium Reports Now @ https://www.researchnester.com/payment/rep-id-223

Ajay Daniel
Research Nester
+1 646 586 9123
email us here